Monday August 24, 2020 0 comments
LONGMONT -- KromaTiD, Inc. today announced it has been awarded a Direct to Phase II SBIR grant by the National Human Genome Research Institute.
The award supports development of a structural variant discovery platform -- dGH DSCVR™ -- enabling efficient discovery of genomic structural causes of rare disease and measurement of unwanted structural rearrangements that occur during gene editing.
The amount of the award was not disclosed.
Single cell analysis with dGH DSCVR will provide data on structural variants at an unparalleled resolution, yielding essential measurements that cannot be made by any other sequencing or cytogenetic method, the company said.
KromaTiD currently provides commercial dGH products and services to industry and academic researchers assessing the integrity of engineered cells modified by CRISPR/Cas-9, base editing and virally mediated gene therapies.
"This funding enables KromaTiD to develop analytical methods for therapeutics generated via CRISPR/Cas-9 and to help identify the genomic structural causes of debilitating diseases,” said Gretchen Pratt, VP of operations.
“With the help of the NHGRI, we are excited to expand the range of technology and services we can offer our customers and collaborators."
According to KromaTiD, dGH is the most sensitive method to measure genomic rearrangements arising from any cause. Using direct, definitive analysis of the genomic structure of many individual cells, the family of dGH assays provides researchers with single-cell unbiased measurements of structural variation, regardless of complexity, heterogeneity or rarity.
This year, with a previous award from NHGRI, KromaTiD completed development of dGH SCREEN, a single cell, whole genome technique for screening cell libraries and batches of engineered cells.
dGH DSCVR extends the capabilities of dGH SCREEN, allowing KromaTiD to discover potentially medically important structural variants, and also identify which genes are impacted by the variant.
When combined, dGH SCREEN and dGH DSCVR will provide medical researchers with unprecedented efficiency in discovering and identifying causes of rare diseases and cancers, KromaTiD said.
"With this SBIR award, the NHGRI is making previously impossible single cell measure of structural variants throughout the human genome not just possible but practical," said KromaTiD's president and CEO, Dr. Christopher Tompkins.
"dGH DSCVR isn't only a new method for discovering the cause of rare diseases and cancers, it is also an essential tool for understanding the outcomes of gene editing, and ultimately the most efficient test for the structural variants that cause disease."